Susan Dillon

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Cowen Investment Management LLC (Cowen Investment Management) is a venture capital subsidiary of Cowen, Inc. founded in 1997. The firm is headquartered in New York.

Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland.

Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA.

The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA.

Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC.

PureSight Advisory LLC provides management software solutions. The private company is based in Newark.

Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.

Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom.

Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA.

DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA.

Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019.

Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.

Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.